Induction of neutralising antibodies restricts the use of human granulocyte/macrophage colony stimulating factor for vaccine studies in rhesus macaques

Vaccine

Volumn 22, Issue 25-26, 2004, Pages 3295-3302

  Eisenblätter, Martin ^a   Stahl Hennig, Christiane ^b   Kuate, Seraphin ^c   Stolte, Nicole ^b   Jasny, Edith ^a   Hahn, Helmut ^a   Pope, Melissa ^d   Tenner Racz, Klara ^e   Racz, Paul ^e   Steinman, Ralph M ^f   Überla, Klaus ^c   Ignatius, Ralf ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b GERMAN PRIMATE CENTER   (Germany)

^c RUHR UNIVERSITY BOCHUM   (Germany)

^d POPULATION COUNCIL   (United States)

^e BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE   (Germany)

^f ROCKEFELLER UNIVERSITY   (United States)

Author keywords

GM CSF; Immunogenicity; Rhesus macaque

Indexed keywords

NEUTRALIZING ANTIBODY; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL COUNT; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOMODULATION; MALE; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY;

ANIMALS; ANTIBODIES, BLOCKING; BLOTTING, WESTERN; CELL SEPARATION; CLONING, MOLECULAR; CYTOKINES; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; MACACA MULATTA; MALE; MONOCYTES; NEUTRALIZATION TESTS; VACCINES;

EID: 4043171299     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2004.03.002     Document Type: Article

References (49)

1. Nath B.M., Schumann K.E., Boyer J.D. The chimpanzee and other non-human-primate models in HIV-1 vaccine research. Trends Microbiol. 8(9):2000;426-431
2. Steinman R.M., Pope M. Exploiting dendritic cells to improve vaccine efficacy. J. Clin. Invest. 109(12):2002;1519-1526
3. Coates P.T., Barratt-Boyes S.M., Donnenberg A.D., Morelli A.E., Murphey-Corb M., Thomson A.W. Strategies for preclinical evaluation of dendritic cell subsets for promotion of transplant tolerance in the nonhuman primate. Hum. Immunol. 63(10):2002;955-965
4. O'Doherty U., Ignatius R., Bhardwaj N., Pope M. Generation of monocyte-derived dendritic cells from precursors in rhesus macaque blood. J. Immunol. Methods. 207(2):1997;185-194
5. Mehlhop E., Villamide L.A., Frank I., et al. Enhanced in vitro stimulation of rhesus macaque dendritic cells for activation of SIV-specific T cell responses. J. Immunol. Methods. 260(1-2):2002;219-234
6. Lu W., Wu X., Lu Y., Guo W., Andrieu J.M. Therapeutic dendritic-cell vaccine for simian AIDS. Nat. Med. 9(1):2003;27-32
7. Ardeshna K.M., Pizzey A.R., Thomas N.S., Orr S., Linch D.C., Devereux S. Monocyte-derived dendritic cells do not proliferate and are not susceptible to retroviral transduction. Br. J. Haematol. 108(4):2000;817-824
8. Belardelli F., Ferrantini M. Cytokines as a link between innate and adaptive antitumor immunity. Trends Immunol. 23(4):2002;201-208
9. Donahue R.E., Wang E.A., Stone D.K., et al. Stimulation of haematopoiesis in primates by continuous infusion of recombinant human GM-CSF. Nature. 321(6073):1986;872-875
10. Geller R.B. Use of cytokines in the treatment of acute myelocytic leukemia: a critical review. J. Clin. Oncol. 14(4):1996;1371-1382
11. Armitage J.O. Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor. Blood. 92(12):1998;4491-4508
12. Wognum A.W., Westerman Y., Visser T.P., Wagemaker G. Distribution of receptors for granulocyte-macrophage colony-stimulating factor on immature CD34+ bone marrow cells, differentiating monomyeloid progenitors, and mature blood cell subsets. Blood. 84(3):1994;764-774
13. Lehner T., Wang Y., Cranage M., et al. Up-regulation of beta-chemokines and down-modulation of CCR5 co-receptors inhibit simian immunodeficiency virus transmission in non-human primates. Immunology. 99(4):2000;569-577
14. Lena P., Villinger F., Giavedoni L., Miller C.J., Rhodes G., Luciw P. Co-immunization of rhesus macaques with plasmid vectors expressing IFN-gamma, GM-CSF, and SIV antigens enhances anti-viral humoral immunity but does not affect viremia after challenge with highly pathogenic virus. Vaccine. 20(Suppl 4):2002;A69-79
15. Sykes K.F., Lewis M.G., Squires B., Johnston S.A. Evaluation of SIV library vaccines with genetic cytokines in a macaque challenge. Vaccine. 20(17/18):2002;2382-2395
16. Rogers W.O., Weiss W.R., Kumar A., et al. Protection of rhesus macaques against lethal Plasmodium knowlesi malaria by a heterologous DNA priming and poxvirus boosting immunization regimen. Infect. Immun. 70(8):2002;4329-4335
17. Kumar S., Villinger F., Oakley M., et al. A DNA vaccine encoding the 42 kDa C-terminus of merozoite surface protein 1 of Plasmodium falciparum induces antibody, interferon-gamma and cytotoxic T cell responses in rhesus monkeys: immuno-stimulatory effects of granulocyte macrophage-colony stimulating factor. Immunol. Lett. 81(1):2002;13-24
18. O'Neill E., Martinez I., Villinger F., et al. Protection by SIV VLP DNA prime/protein boost following mucosal SIV challenge is markedly enhanced by IL-12/GM-CSF co-administration. J. Med. Primatol. 31(4-5):2002;217-227
19. Ragnhammar P., Wadhwa M. Neutralising antibodies to granulocyte- macrophage colony stimulating factor (GM-CSF) in carcinoma patients following GM-CSF combination therapy. Med. Oncol. 13(3):1996;161-166
20. Wadhwa M., Skog A.L., Bird C., et al. Immunogenicity of granulocyte-macrophage colony-stimulating factor (GM-CSF) products in patients undergoing combination therapy with GM-CSF. Clin. Cancer Res. 5(6):1999;1353-1361
21. Stahl C.P., Winton E.F., Monroe M.C., et al. Recombinant human granulocyte-macrophage colony-stimulating factor promotes megakaryocyte maturation in nonhuman primates. Exp. Hematol. 19(8):1991;810-816
22. Carter D.L., Shieh T.M., Blosser R.L., et al. CD56 identifies monocytes and not natural killer cells in rhesus macaques. Cytometry. 37(1):1999;41-50
23. Hutchinson K.L., Villinger F., Miranda M.E., Ksiazek T.G., Peters C.J., Rollin P.E. Multiplex analysis of cytokines in the blood of cynomolgus macaques naturally infected with Ebola virus (Reston serotype). J. Med. Virol. 65(3):2001;561-566
24. He T.C., Zhou S., da Costa L.T., Yu J., Kinzler K.W., Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc. Natl. Acad. Sci. U.S.A. 95(5):1998;2509-2514
25. Ignatius R., Mahnke K., Rivera M., et al. Presentation of proteins encapsulated in sterically stabilized liposomes by dendritic cells initiates CD8(+) T-cell responses in vivo. Blood. 96(10):2000;3505-3513
26. Sallusto F., Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 179(4):1994;1109-1118
27. Monroy R.L., Skelly R.R., MacVittie T.J., et al. The effect of recombinant GM-CSF on the recovery of monkeys transplanted with autologous bone marrow. Blood. 70(5):1987;1696-1699
28. Geissler K., Valent P., Mayer P., et al. Recombinant human interleukin-3 expands the pool of circulating hematopoietic progenitor cells in primates-synergism with recombinant human granulocyte/macrophage colony-stimulating factor. Blood. 75(12):1990;2305-2310
29. Stahl C.P., Winton E.F., Monroe M.C., et al. Differential effects of sequential, simultaneous, and single agent interleukin-3 and granulocyte-macrophage colony-stimulating factor on megakaryocyte maturation and platelet response in primates. Blood. 80(10):1992;2479-2485
30. Williams D.E., Dunn J.T., Park L.S., et al. A GM-CSF/IL-3 fusion protein promotes neutrophil and platelet recovery in sublethally irradiated rhesus monkeys. Biotechnol. Ther. 4(1-2):1993;17-29
31. Farese A.M., Williams D.E., Seiler F.R., MacVittie T.J. Combination protocols of cytokine therapy with interleukin-3 and granulocyte-macrophage colony-stimulating factor in a primate model of radiation-induced marrow aplasia. Blood. 82(10):1993;3012-3018
32. Myers L.A., Boyce J.T., Robison R.L. The tolerability and pharmacology of interleukin-6 administered in combination with GM-CSF or G-CSF in the rhesus monkey. Toxicology. 101(3):1995;157-166
33. Neelis K.J., Hartong S.C., Egeland T., Thomas G.R., Eaton D.L., Wagemaker G. The efficacy of single-dose administration of thrombopoietin with coadministration of either granulocyte/macrophage or granulocyte colony-stimulating factor in myelosuppressed rhesus monkeys. Blood. 90(7):1997;2565-2573
34. Davis T.A., Monroy R.L., Skelly R.R., Donahue R.E., MacVittie T.J. Differential augmentation of in vivo natural killer cytotoxicity in normal primates with recombinant human interleukin-1 and granulocyte-macrophage colony-stimulating factor. Clin. Exp. Immunol. 79(3):1990;436-442
35. Svenson M., Hansen M.B., Ross C., et al. Antibody to granulocyte- macrophage colony-stimulating factor is a dominant anti-cytokine activity in human IgG preparations. Blood. 91(6):1998;2054-2061
36. Meager A., Wadhwa M., Bird C., et al. Spontaneously occurring neutralizing antibodies against granulocyte-macrophage colony-stimulating factor in patients with autoimmune disease. Immunology. 97(3):1999;526-532
37. Meager A., Wadhwa M., Dilger P., et al. Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and/or myasthenia gravis. Clin. Exp. Immunol. 132(1):2003;128-136
38. Gribben J.G., Devereux S., Thomas N.S., et al. Development of antibodies to unprotected glycosylation sites on recombinant human GM-CSF. Lancet. 335(8687):1990;434-437
39. Ragnhammar P., Friesen H.J., Frodin J.E., et al. Induction of anti-recombinant human granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived) antibodies and clinical effects in nonimmunocompromised patients. Blood. 84(12):1994;4078-4087
40. Vial T., Descotes J. Immune-mediated side-effects of cytokines in humans. Toxicology. 105(1):1995;31-57
41. Wadhwa M., Bird C., Fagerberg J., et al. Production of neutralizing granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies in carcinoma patients following GM-CSF combination therapy. Clin. Exp. Immunol. 104(2):1996;351-358
42. Ullenhag G., Bird C., Ragnhammar P., et al. Incidence of GM-CSF antibodies in cancer patients receiving GM-CSF for immunostimulation. Clin. Immunol. 99(1):2001;65-74
43. Kitamura T., Tanaka N., Watanabe J., et al. Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 190(6):1999;875-880
44. Bonfield T.L., Russell D., Burgess S., Malur A., Kavuru M.S., Thomassen M.J. Autoantibodies against granulocyte macrophage colony-stimulating factor are diagnostic for pulmonary alveolar proteinosis. Am. J. Respir. Cell Mol. Biol. 27(4):2002;481-486
45. Scheibenbogen C., Schadendorf D., Bechrakis N.E., et al. Effects of granulocyte-macrophage colony-stimulating factor and foreign helper protein as immunologic adjuvants on the T-cell response to vaccination with tyrosinase peptides. Int. J. Cancer. 104(2):2003;188-194
46. Slingluff C.L. Jr., Petroni G.R., Yamshchikov G.V., et al. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J. Clin. Oncol. 21(21):2003;4016-4026
47. Sasaki M.G., Foccacia R., de Messias-Reason I.J. Efficacy of granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant for hepatitis B virus in patients with HIV infection. Vaccine. 21(31):2003;4545-4549
48. Singh N.P., Mandal S.K., Thakur A., et al. Efficacy of GM-CSF as an adjuvant to hepatitis B vaccination in patients with chronic renal failure-results of a prospective, randomized trial. Ren. Fail. 25(2):2003;255-266
49. Bukreyev A., Skiadopoulos M.H., McAuliffe J., Murphy B.R., Collins P.L., Schmidt A.C. More antibody with less antigen: can immunogenicity of attenuated live virus vaccines be improved. Proc. Natl. Acad. Sci. U.S.A. 99(26):2002;16987-16991